SCHEDULE: Affinity Funds Disclose 7.77% Stake in Sutro Biopharma
Beneficial Ownership Report
Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have disclosed a combined beneficial ownership of 7.77% in Sutro Biopharma, Inc. common stock.
Summary
- Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC reported beneficial ownership of 6,583,772 shares of Sutro Biopharma, Inc. common stock.
- This represents 7.77% of the outstanding shares of Sutro Biopharma, Inc.
- The reporting persons have shared voting power and shared dispositive power over all 6,583,772 shares.
- The percentage of class is based on 84,774,177 shares outstanding as of August 1, 2025, as reported in Sutro Biopharma's Quarterly Report on Form 10-Q filed on August 7, 2025.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine beneficial ownership disclosure (Schedule 13G) and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply reports an institutional investor's stake.
Industry Context
This filing indicates a significant institutional investment in Sutro Biopharma, a company operating in the biopharmaceutical sector. Such disclosures are common as institutional investors cross ownership thresholds, reflecting their investment strategies within the healthcare industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Affinity Healthcare Fund and Affinity Asset Advisors may be viewed as a vote of confidence by some investors, potentially influencing market perception.
- Company Management: Awareness of a large institutional holder may influence strategic decisions or communication strategies, though the filing certifies no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-08-01 | Date as of which 84,774,177 shares of Common Stock of the Issuer were outstanding, used for percentage calculation. |
| 2025-08-07 | Date Sutro Biopharma, Inc. filed its Quarterly Report on Form 10-Q, which provided the outstanding share count. |
| 2025-10-16 | Date of event which required the filing of this statement. |
| 2025-10-23 | Date the Schedule 13G was signed by Andrew Weinstein on behalf of both reporting persons. |
Keywords
Sutro Biopharma, Affinity Healthcare Fund, Affinity Asset Advisors, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.